A recent European Urology Oncology study assessed the mortality risks, based on the Gleason score and clinical parameters, in patients with prostate cancer.
Genentech, Blueprint tout full approval for Gavreto in rare type of lung cancer
Genentech and Blueprint Medicines scored a full FDA approval on Wednesday for Gavreto’s use in a small subset of non-small cell lung cancer patients, nearly